Anthracycline induced cardiotoxicity: A systematic review
This project report is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2017
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Project report |
| Idioma: | English |
| Publicado em: |
BRAC University
2018
|
| Assuntos: | |
| Acesso em linha: | http://hdl.handle.net/10361/9487 |
| id |
10361-9487 |
|---|---|
| record_format |
dspace |
| spelling |
10361-94872019-09-30T03:19:06Z Anthracycline induced cardiotoxicity: A systematic review Azam, Faruque Talukder, Dr. Md. Mesbah Uddin Department of Pharmacy, BRAC University Cardiotoxicity Anthracycline Cancer This project report is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2017 Cataloged from PDF version of project report. Includes bibliographical references (page 68-79). Cancer cure currently involves a combination of integrative treatments; chemotherapy, radiotherapy, and surgery to extend life and deliver sustainability to the survivors. Among all the classes of chemotherapeutics, anthracycline group has multiple wellestablished therapeutic uses. Anthracyclines can be used as antibiotics and also effective over a wide spectrum of malignancies. However, they also possess undesired cardiac toxicity; being the major drawback of anthracycline chemotherapy, which restricts their clinical use. In retrospective, detrimental effects on heart associated with Anthracycline- Induced-Cardiotoxicity (AIC) is irreversible and a challenging concern in the field of cardio-oncology, considering other adverse effects. Despite its dose-limiting cardiotoxicity, anthracycline drugs are being widely used in chemotherapy because of their effectiveness over a broad spectrum of cancers and solid tumors. In addition to their versatile therapeutic activity, dose-dependent congestive heart failure and accumulation of toxic drug metabolites in cardiomyocytes may possibly be the worst consequences of cardiotoxicity caused by doxorubicin and other anthracyclines. Cardiotoxicity related to anthracyclines yet remains to be an intractable clinical conundrum for both cardiologists and oncologists. The mechanism of AIC possibly involves oxidative stress of myocardium triggered by free radicals and consequently may lead to apoptosis and lipid peroxidation, or involves immunologic responses. Notably, various other mechanisms may play an underlying role to predispose AIC. In the strategy to mitigate AIC, dexrazoxane has shown to have promising cardioprotective action and further used to lessen symptoms of cardiotoxicity. Although the impact of other cardioprotective agents such as β-blockers, ACEI (Angiotensin Converting Enzyme Inhibitors), and lipid lowering agents may reduce AIC to some degree, still significant cardiovascular complication may occur. Despite the reduction in cumulative dose of anthracyclines and concomitant use of iron chelator dexrazoxane, no other agent has absolute evidence in regard to treatment or protection against AIC. In this article, we reviewed the incidence of cardiotoxicity induced by mainly anthracyclines as well as their pathogenesis, detection, function of biomarkers and protective agents used to ameliorate cardiovascular complications. Besides, in particular, we found significant cardiovascular anomalies in ADR data of doxorubicin male patients and also a notable discrepancy in ADR data of docetaxel in different geographical regions. Faruque Azam B. Pharmacy. 2018-02-15T10:24:24Z 2018-02-15T10:24:24Z 2017 2017-07 Project report ID 13146012 http://hdl.handle.net/10361/9487 en BRAC University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 79 pages. application/pdf BRAC University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Cardiotoxicity Anthracycline Cancer |
| spellingShingle |
Cardiotoxicity Anthracycline Cancer Azam, Faruque Anthracycline induced cardiotoxicity: A systematic review |
| description |
This project report is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2017 |
| author2 |
Talukder, Dr. Md. Mesbah Uddin |
| author_facet |
Talukder, Dr. Md. Mesbah Uddin Azam, Faruque |
| format |
Project report |
| author |
Azam, Faruque |
| author_sort |
Azam, Faruque |
| title |
Anthracycline induced cardiotoxicity: A systematic review |
| title_short |
Anthracycline induced cardiotoxicity: A systematic review |
| title_full |
Anthracycline induced cardiotoxicity: A systematic review |
| title_fullStr |
Anthracycline induced cardiotoxicity: A systematic review |
| title_full_unstemmed |
Anthracycline induced cardiotoxicity: A systematic review |
| title_sort |
anthracycline induced cardiotoxicity: a systematic review |
| publisher |
BRAC University |
| publishDate |
2018 |
| url |
http://hdl.handle.net/10361/9487 |
| work_keys_str_mv |
AT azamfaruque anthracyclineinducedcardiotoxicityasystematicreview |
| _version_ |
1814307981384220672 |